AstraZeneca Soliris approved in China for adults with refractory generalised myasthenia gravis Ruchika Sharma14 Jun 2023 10:00 AM ISTCambridge: AstraZeneca has announced that Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory...
AstraZeneca, Quell Therapeutics ink pact for engineered T-regulatory cell therapies for autoimmune diseases Ruchika Sharma11 Jun 2023 10:30 AM ISTQuell will receive USD 85 million upfront from AstraZeneca, which comprises a predominant cash payment and an equity investment.
AstraZeneca-Sanofi Nirsevimab unanimously recommended by USFDA Advisory Committee for prevention of RSV in infants Ruchika Sharma9 Jun 2023 1:30 PM ISTLondon: The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and...
USFDA nod to AstraZeneca, MSD's Lynparza plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Ruchika Sharma2 Jun 2023 3:30 PM ISTRahway: AstraZeneca and Merck, known as MSD outside of the United States and Canada, has announced that LYNPARZA in combination with abiraterone...
AstraZeneca discontinues brazikumab inflammatory bowel disease development programme Ruchika Sharma2 Jun 2023 1:30 PM ISTCambridge: AstraZeneca has announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development programme, an anti-IL-23...
AstraZeneca Pharma India names Bhavana Agrawal as new CFO Ruchika Sharma1 Jun 2023 5:30 PM ISTBangalore: AstraZeneca Pharma India Ltd., a leading biopharmaceutical company, has announced the appointment of Bhavana Agrawal as Chief Finance...
AstraZeneca Ultomiris gets Japanese nod for prevention of relapses in patients with neuromyelitis optica spectrum disorder Ruchika Sharma28 May 2023 11:00 AM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
AstraZeneca to leave leading US drug lobby group Ruchika Sharma17 May 2023 1:30 PM ISTAstraZeneca's exit follows those of AbbVie, maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs.
AtraZeneca's Ultomiris approved in EU for adults with neuromyelitis optica spectrum disorder Ruchika Sharma12 May 2023 1:30 PM ISTNeuromyelitis optica spectrum disorder is a rare and debilitating autoimmune disease that affects the central nervous system including the spine and...
AstraZeneca Farxiga approved in US to reduce risk of cardiovascular death, hospitalisation for heart failure to broader range of patients Ruchika Sharma10 May 2023 12:30 PM ISTCambridge: AstraZeneca has announced that Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death,...
AstraZeneca Koselugo gets Chinese nod for paediatric patients with neurofibromatosis type 1, plexiform neurofibromas Ruchika Sharma9 May 2023 12:30 PM ISTIn addition to China, Koselugo is also approved in the US, EU, Japan and several other countries for the treatment of paediatric patients with NF1 and...
DCGI okays AstraZeneca's breast cancer drug Trastuzumab deruxtecan Ruchika Sharma4 May 2023 12:41 PM ISTThe HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of multiple tumours including breast, gastric, lung and...
